Orchestra BioMed Holdings, Inc. (OBIO)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

0 15M 30M 45M Q1 '22: 866K Q2 '22: 401K Q3 '22: 1.2M Q4 '22: 1.1M Q1 '23: 1.2M Q2 '23: 915K Q3 '23: 419K Q4 '23: 262K Q1 '24: 620K Q2 '24: 778K Q3 '24: 987K Q4 '24: 253K Q1 '25: 868K Q2 '25: 836K Q3 '25: 861K Q4 '25: 30.9M Q1 '26: 110K Q2 '26: 88K Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Gross Profit Quarterly

0 15M 30M 45M Q1 '22: 824K Q2 '22: 341K Q3 '22: 1.1M Q4 '22: 1.1M Q1 '23: 1.1M Q2 '23: 861K Q3 '23: 378K Q4 '23: 215K Q1 '24: 586K Q2 '24: 734K Q3 '24: 919K Q4 '24: 195K Q1 '25: 824K Q2 '25: 790K Q3 '25: 812K Q4 '25: 30.9M Q1 '26: 78K Q2 '26: 63K Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Revenue minus cost of sales. This filer tags no gross profit of its own..

Operating Income Quarterly

-24M -16M -8M 0 8M 16M 24M Q3 '21: -94.4K Q4 '21: -92K Q1 '22: -5.1M Q2 '22: -7.6M Q3 '22: -10.1M Q4 '22: -9.8M Q1 '23: -11.5M Q2 '23: -13M Q3 '23: -14.5M Q4 '23: -12.5M Q1 '24: -14.4M Q2 '24: -16.9M Q3 '24: -16.3M Q4 '24: -16.7M Q1 '25: -18.9M Q2 '25: -19.3M Q3 '25: -20.3M Q4 '25: 6.8M Q1 '26: -22.1M Q2 '26: -22.4M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income Quarterly

-27M -18M -9M 0 9M 18M 27M Q3 '21: -90.4K Q4 '21: -88K Q1 '22: -5.7M Q2 '22: -7.8M Q3 '22: -10.3M Q4 '22: -9.8M Q1 '23: -10.9M Q2 '23: -12M Q3 '23: -13.3M Q4 '23: -12.8M Q1 '24: -13.5M Q2 '24: -16M Q3 '24: -15.4M Q4 '24: -16.2M Q1 '25: -18.8M Q2 '25: -19.4M Q3 '25: -20.8M Q4 '25: 6.2M Q1 '26: -20.7M Q2 '26: -23.8M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Cost of Revenue Quarterly

0 25K 50K 75K Q1 '22: 42K Q2 '22: 60K Q3 '22: 56K Q4 '22: 53K Q1 '23: 44K Q2 '23: 54K Q3 '23: 41K Q4 '23: 47K Q1 '24: 34K Q2 '24: 44K Q3 '24: 68K Q4 '24: 58K Q1 '25: 44K Q2 '25: 46K Q3 '25: 49K Q4 '25: 51K Q1 '26: 32K Q2 '26: 25K Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating Cash Flow Quarterly

-24M -16M -8M 0 8M 16M 24M Q3 '21: -128K Q4 '21: -28.8K Q1 '22: -5.3M Q2 '22: -8M Q3 '22: -7.3M Q4 '22: -8.7M Q1 '23: -14.4M Q2 '23: -10.5M Q3 '23: -10.3M Q4 '23: -11M Q1 '24: -13.1M Q2 '24: -10.2M Q3 '24: -13.7M Q4 '24: -13.5M Q1 '25: -16.6M Q2 '25: -15.5M Q3 '25: -14.6M Q4 '25: -2.3M Q1 '26: -22.2M Q2 '26: -19.3M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow Quarterly

-24M -16M -8M 0 8M 16M 24M Q1 '22: -5.4M Q2 '22: -8.2M Q3 '22: -7.5M Q4 '22: -8.8M Q1 '23: -14.4M Q2 '23: -10.5M Q3 '23: -10.3M Q4 '23: -11M Q1 '24: -13.1M Q2 '24: -10.3M Q3 '24: -13.8M Q4 '24: -13.6M Q1 '25: -16.7M Q2 '25: -15.6M Q3 '25: -14.9M Q4 '25: -2.3M Q1 '26: -22.4M Q2 '26: -19.6M Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 25M 50M 75M Q1 '21: 20.4M Q2 '21: 20.4M Q3 '21: 20.4M Q1 '22: 9.2M Q2 '22: 10.1M Q3 '22: 20.2M Q1 '23: 27.6M Q2 '23: 34.6M Q3 '23: 35.2M Q1 '24: 35.8M Q2 '24: 35.8M Q3 '24: 37.6M Q1 '25: 38.2M Q2 '25: 38.4M Q3 '25: 52.2M Q1 '26: 62.7M Q2 '26: 63.8M Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-2.40 -1.60 -0.80 0.00 0.80 1.60 2.40 Q3 '21: 0.00 Q4 '21: -0.01 Q1 '22: -0.63 Q2 '22: -1.40 Q3 '22: -1.91 Q4 '22: -2.34 Q1 '23: -2.12 Q2 '23: -1.70 Q3 '23: -1.57 Q4 '23: -1.50 Q1 '24: -1.48 Q2 '24: -1.58 Q3 '24: -1.61 Q4 '24: -1.67 Q1 '25: -1.78 Q2 '25: -1.83 Q3 '25: -1.82 Q4 '25: -1.11 Q1 '26: -0.95 Q2 '26: -0.83 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.